AccessibilityHelpAbout Us

Braveheart Bio(NASDAQ) BRVE

Market Cap$2.63BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2026)-2%
5 YearN/A
1 YearN/A
1 Month-9%
$25.02
-14.32%
-4.18Today
After hours$25.02+$0.00 (+0.00%)
Braveheart Bio last closing stock price
MetricPriceDate
Last closeUSD 25.022026-09-21
Braveheart Bio stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-7.4%USD 27.022026-09-14
1 month-9.28%USD 27.582026-08-21
Since inception-2.01%USD 29.802026-08-06

Braveheart Bio Financials at a Glance

Market Cap

$2.63BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$29.75

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-1.11 (Low)

Price

$25.02

Volume

1,570,083.085

Open

$28.90

Previous Close

$25.02

Daily Range

$24.63 - $28.90

52-Week Range

$18.00 - $32.00

Estimated Earnings Date

Dec 2, 2026

BRVE News

PiggyBank-BuyAlert-Purple.png

Braveheart Bio CFO Acquires 27,777 Shares for $500,000. Is This a Signal BRVE IPO Is a Success?

Brendan CoffeyAug 10, 2026
BuyAlert-Green.png

Braveheart Bio Chairman Chris Viehbacher Buys $1.5M Shares at IPO. What Does This Mean for Investors?

Brendan CoffeyAug 10, 2026
BuyAlert-Purple.png

Braveheart Bio CEO Travis Murdoch Buys 83,333 Shares for $1.5 Million. Is This a Buy Signal for Investors?

Brendan CoffeyAug 10, 2026

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Braveheart Bio

Braveheart Bio, Inc. creates medicines for patients with heart disease. Its treatments help people whose heart muscles have grown too thick. These drugs aim to make the heart pump more efficiently.

Focus on Heart Health

  • BHB-1893: An oral pill that slows down certain proteins in heart muscle to help the heart relax; currently undergoing Phase 3 clinical testing.
  • Cardiac Myosin Inhibitors: Small molecules designed to reduce heart muscle over-activity; intended to be easier for doctors to prescribe than existing options.

Moving Closer to Market

  • Entered an exclusive license agreement with Jiangsu Hengrui Pharmaceuticals in September 2025 to develop heart treatments.
  • Initiated the LIONHEART-HCM Phase 3 clinical trial in 2026 to test the safety and efficacy of its lead drug candidate.
  • Completed an initial public offering in August 2026 to fund the development of its medical pipeline.
  • Planned the start of a second Phase 3 clinical trial for non-obstructive heart disease in the first half of 2027.

What Makes the Drug Different?

The company focuses on heart treatments that work quickly and require less frequent monitoring than current therapies. It holds exclusive rights to develop and sell its lead candidate in most global markets outside of Mainland China and nearby regions.

Financing the Science

  • Net loss was $29.3 million for the six-month period ended June 30, 2026, compared to $0.5 million for the same period in 2025.
  • Cash and cash equivalents totaled $122.8 million as of June 30, 2026.
  • Initial public offering net proceeds were approximately $404.5 million in August 2026.
  • Research and development expenses were $22.0 million for the six-month period ended June 30, 2026.
  • Management believes current capital will fund operations into 2029.

Evolution of the Business

Braveheart has transitioned from a private startup to a public biotechnology firm focused on late-stage clinical trials. Its progress relies on successfully navigating the regulatory approval process for its cardiovascular therapies.

AI Generated • Sep 9, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

49

CEO

Travis Murdoch, MD

Website

www.braveheart.bio

Headquarters

San Francisco, CA 94129, US

BRVE Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

0.00%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

$2.63BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

90.04M

Volume

1.57M

Avg. Volume

497.64K

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Braveheart Bio Performance Analysis

Braveheart Bio annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20252025-12-31USD 0N/A
Braveheart Bio annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20252025-12-31USD -0.73N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$0.00

N/A

Gross Margin

N/A

N/A

Market Cap

$2.63BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

49

N/A

Net Income

-$14.99

N/A

EBITDA

-$15.88

N/A

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$123.41

N/A

Total Debt

$0.58

N/A

Accounts Receivable

N/A

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.20

N/A

Short Term Debt

$0.38

N/A

Return on Assets

N/A

N/A

Return on Invested Capital

N/A

N/A

Free Cash Flow

-$16.94

N/A

Operating Cash Flow

-$16.95

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,763.63+0.01%
^DJIDJI
$52,032.71+0.01%
^IXICNASDAQ
$27,092.05+0.02%
BTCBitcoin
$85,915.00+0.06%

Trending Stocks

Symbol / CompanyPricePrice Chg
WBDWarner Bros. Discovery
$30.80+10.79%
GRMLGreenland Mines
$9.42+230.53%
INTCIntel
$121.78+12.14%
NVDANvidia
$227.38+2.30%

Questions About BRVE

What is the current price of Braveheart Bio?

Braveheart Bio is trading at $25.02 per share.

What is the 52-week range for Braveheart Bio?

Over the past 52 weeks, Braveheart Bio has traded between $18.00 and $32.00.

How much debt does Braveheart Bio have?

As of the most recent reporting period, Braveheart Bio reported total debt of $575.00K.

How much cash does Braveheart Bio have on hand?

Braveheart Bio reported $122.83M in cash and cash equivalents in its most recent financial results.

What is Braveheart Bio’s dividend yield?

Braveheart Bio does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services